Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.54 |
| ▸ | BRAF | P15056 | 8/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882755 | 0.90 | MET (0.56) | KDRAXLMET | |
| SCHEMBL4884736 | 0.87 | AXL (0.59) | KDRAXLMET | |
| SCHEMBL4884069 | 0.85 | MET (0.52) | KDRBRAFAXLMET | |
| SCHEMBL4728517 | 0.82 | MET (0.62) | KDRAXLMET | |
| SCHEMBL4888377 | 0.80 | AXL (0.49) | KDRBRAFAXLMET | |
| SCHEMBL4887103 | 0.79 | AXL (0.62) | KDRAXLMET | |
| SCHEMBL4888445 | 0.78 | MET (0.56) | KDRBRAFMET | |
| SCHEMBL4889760 | 0.76 | AXL (0.59) | KDRBRAFAXLMET | |
| SCHEMBL4329349 | 0.75 | AXL (0.54) | KDRBRAFAXLMET | |
| SCHEMBL4882739 | 0.75 | KDR (0.55) | KDRBRAFAXLMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | KDR 746/4885BRAF 26/4885AXL 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.